Fernandes André, Patricio Joao Nuno, Jorge Rita, Nazareth Raquel, Pereira Carlos S
Internal Medicine, Hospital Beatriz Ângelo, Loures, PRT.
Intensive Care Unit, Hospital Beatriz Ângelo, Loures, PRT.
Cureus. 2024 Feb 13;16(2):e54108. doi: 10.7759/cureus.54108. eCollection 2024 Feb.
Introduction Ventilator-associated pneumonia (VAP) is the most common infectious complication related to admission to an Intensive Treatment Unit (ITU). Ventilator-associated lower respiratory tract infection (VA-LRTI) is a broader diagnosis than VAP. By disregarding radiological criteria, it will include both VAP and ventilator-associated tracheobronchitis. This study, conducted in the setting of a Portuguese ITU, aims to study the incidence, microbiology and clinical outcome of VA-LRTI and its association with COVID-19. Methods A retrospective cohort study included patients admitted to a Portuguese ITU who underwent invasive mechanical ventilation (IMV) for over 48 hours between 01/01/2021 and 31/12/2021. The Hospitals in Europe Link for Infection Control through Surveillance (HELICS) criteria were applied, disregarding the radiological criteria, for the diagnosis of VA-LRTI. Results The group of patients with COVID-19 had 46.38 episodes of VA-LRTI/1000 days of ventilation, while patients without COVID-19 had 16.35 episodes/1000 days of ventilation (RR 2.78, p < 0.001). Of the 85 microorganisms isolated, 82% were gram-negative microorganisms, with species of the genus being the most prevalent (22.4%). There was a lower prevalence of beta-lactam-resistant organisms in patients with COVID-19 (RR 0.35, p = 0.031). The development of VA-LRTI is associated with longer times of IMV (difference in medians 10 days, p < 0.001), but with no significant differences in mortality (RR 1.21, p = 0.14). Discussion Patients with COVID-19 seem more predisposed to developing VA-LRTI, possibly due to intrinsic characteristics of the disease. Although no increase in mortality has been demonstrated, VA-LRTI can entail important costs related to morbidity, antibiotic pressure and economic costs that must be considered.
引言 呼吸机相关性肺炎(VAP)是与入住重症监护病房(ITU)相关的最常见感染性并发症。呼吸机相关性下呼吸道感染(VA-LRTI)的诊断范围比VAP更广。不考虑影像学标准,它将包括VAP和呼吸机相关性气管支气管炎。本研究在葡萄牙的一个ITU环境中进行,旨在研究VA-LRTI的发病率、微生物学和临床结局及其与COVID-19的关联。方法 一项回顾性队列研究纳入了2021年1月1日至2021年12月31日期间在葡萄牙ITU接受有创机械通气(IMV)超过48小时的患者。采用欧洲医院感染控制监测网络(HELICS)标准,不考虑影像学标准,用于诊断VA-LRTI。结果 COVID-19患者组的VA-LRTI发生率为46.38例/1000天通气时间,而无COVID-19的患者为16.35例/1000天通气时间(相对危险度2.78,p<0.001)。在分离出的85种微生物中,82%为革兰氏阴性微生物,其中 属的菌种最为常见(22.4%)。COVID-19患者中对β-内酰胺耐药的微生物患病率较低(相对危险度0.35,p = 0.031)。VA-LRTI的发生与IMV时间延长有关(中位数差异为10天,p<0.001),但在死亡率方面无显著差异(相对危险度1.21,p = 0.14)。讨论 COVID-19患者似乎更容易发生VA-LRTI,可能是由于该疾病的内在特征。虽然尚未证明死亡率增加,但VA-LRTI可能带来与发病率、抗生素压力和经济成本相关的重要费用,必须予以考虑。